Australian research on a combination antiviral therapy for COVID-19 has been boosted with new funding from the Medical Research Future Fund (MRFF).
Almost $1 million in MRFF funding will support a WEHI-led drug discovery program to develop a powerful therapeutic combination targeting two proteins that help the virus replicate.
The dual approach is designed to fight the emergence of antiviral resistance, a key threat with existing COVID-19 treatments that target a single protein.
At a glance
- More than $999,600 in new funding awarded by MRFF for drug discovery research working towards a combination antiviral for COVID-19.
- A multi-disciplinary team will target two key proteins in a combination treatment, to stop the virus replicating and prevent the selection of resistant strains.
- One of the targeted proteins is linked to the body’s immune response, offering hope of potential benefit for the treatment of long COVID.
Professor Guillaume Lessene (WEHI), Professor David
Komander (WEHI), Professor Susan Charman (MIPS),
Dr Brad Sleebs (WEHI), Associate Professor
/Public Release. View in full here.
